Overview

Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase

Status:
Not yet recruiting
Trial end date:
2021-03-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, controlled, double-blind, phase III study.
Phase:
Phase 3
Details
Lead Sponsor:
Sun Yat-sen University
Collaborator:
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Treatments:
Aprepitant
Fosaprepitant
Olanzapine